

Todd A Fehniger

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6561229/todd-a-fehniger-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

159
papers

12,855
citations

46
h-index

113
g-index

173
ext. papers

15,104
ext. citations

6.2
avg, IF

6.07
L-index

#	Paper	IF	Citations
159	The biology of human natural killer-cell subsets. <i>Trends in Immunology</i> , 2001 , 22, 633-40	14.4	2075
158	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. <i>Blood</i> , 2001 , 97, 3146-51	2.2	1023
157	Interleukin 15: biology and relevance to human disease. <i>Blood</i> , 2001 , 97, 14-32	2.2	758
156	CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. <i>Blood</i> , 2003 , 101, 3052-7	2.2	664
155	Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. <i>Immunity</i> , 2007 , 27, 635-46	32.3	543
154	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016 , 375, 2023-2036	59.2	493
153	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
152	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002 , 100, 1935-47	2.2	405
151	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. <i>Science Translational Medicine</i> , 2016 , 8, 357ra123	17.5	403
150	NK cell and DC interactions. <i>Trends in Immunology</i> , 2004 , 25, 47-52	14.4	361
149	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1	359
148	Cytokine activation induces human memory-like NK cells. <i>Blood</i> , 2012 , 120, 4751-60	2.2	344
147	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. <i>Blood</i> , 2002 , 100, 3633-8	2.2	341
146	Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. <i>Immunity</i> , 2007 , 26, 798-811	32.3	311
145	Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2001 , 193, 219-31	16.6	292
144	Interleukin-2 and interleukin-15: immunotherapy for cancer. <i>Cytokine and Growth Factor Reviews</i> , 2002 , 13, 169-83	17.9	223
143	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018 , 131, 2515-2527	2.2	194

142	Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15. <i>Blood</i> , 1998 , 92, 3647-3657	2.2	176
141	Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 463-73	4.7	158
140	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011 , 118, 5119-25	2.2	152
139	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. <i>Journal of Clinical Investigation</i> , 2017 , 127, 4042-4058	15.9	131
138	Next-generation sequencing identifies the natural killer cell microRNA transcriptome. <i>Genome Research</i> , 2010 , 20, 1590-604	9.7	111
137	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017 , 129, 473-483	2.2	98
136	The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016 , 22, 596-608	12.9	97
135	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1828-33	2.2	95
134	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018 , 131, 182-190	2.2	92
133	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1851-1860	4.7	91
132	CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. <i>European Journal of Immunology</i> , 1997 , 27, 354-60	6.1	90
131	Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. <i>Scientifica</i> , 2014 , 2014, 205796	2.6	82
130	Biology and clinical impact of human natural killer cells. <i>International Journal of Hematology</i> , 2003 , 78, 7-17	2.3	80
129	Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1646-52	4.7	76
128	Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2000 , 106, 117-24	15.9	76
127	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 46-52	4.7	72
126	Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. <i>Cancer Immunology, Immunotherapy</i> , 1998 , 46, 318-26	7.4	66
125	Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. <i>Blood</i> , 2009 , 113, 1002-5	2.2	64

124	Harnessing NK Cell Memory for Cancer Immunotherapy. <i>Trends in Immunology</i> , 2016 , 37, 877-888	14.4	58
123	Latent herpesvirus infection arms NK cells. <i>Blood</i> , 2010 , 115, 4377-83	2.2	58
122	Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. <i>Journal of Immunology</i> , 2000 , 164, 1643-7	5.3	58
121	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. <i>JCI Insight</i> , 2017 , 2,	9.9	58
120	Complete characterization of the microRNAome in a patient with acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 5316-26	2.2	56
119	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020 , 136, 2308-2318	2.2	55
118	Lenalidomide-mediated enhanced translation of C/EBP β 30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 159-69	2.2	53
117	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2017 , 133, 61-77	14.3	52
116	Human Cytokine-Induced Memory-Like Natural Killer Cells. <i>Journal of Innate Immunity</i> , 2015 , 7, 563-71	6.9	51
115	MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. <i>Journal of Immunology</i> , 2012 , 188, 3019-30	5.3	51
114	MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. <i>Journal of Immunology</i> , 2013 , 191, 5904-13	5.3	47
113	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1696-1701	4.7	44
112	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and Fc γ RIIIa-Triggered Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 398-404	4.7	40
111	MicroRNA regulation of natural killer cells. <i>Frontiers in Immunology</i> , 2013 , 4, 44	8.4	39
110	Fatal leukemia in interleukin-15 transgenic mice. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 223-30	2.1	39
109	A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1581-1589	4.7	38
108	A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nature Genetics</i> , 2018 , 50, 1735-1743	36.3	38
107	MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. <i>Journal of Immunology</i> , 2015 , 195, 2806-17	5.3	37

106	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 211-8	3.6	35
105	Improving natural killer cell cancer immunotherapy. <i>Current Opinion in Organ Transplantation</i> , 2015 , 20, 671-80	2.5	34
104	microRNA management of NK-cell developmental and functional programs. <i>European Journal of Immunology</i> , 2014 , 44, 2862-8	6.1	33
103	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016 , 101, e465-e468	6.6	32
102	Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells In Vivo. <i>Blood</i> , 1997 , 90, 3647-3653	2.2	31
101	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002 , 8, 2812-9	12.9	31
100	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020 , 10, 1854-1871	24.4	30
99	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 648-653	4.7	28
98	PTEN regulates natural killer cell trafficking in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E700-9	11.5	28
97	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	27
96	Differential expression of granzyme B and C in murine cytotoxic lymphocytes. <i>Journal of Immunology</i> , 2009 , 182, 6287-97	5.3	27
95	New directions in natural killer cell-based immunotherapy of human cancer. <i>Expert Opinion on Biological Therapy</i> , 2003 , 3, 237-50	5.4	27
94	Ontogeny and expansion of human natural killer cells: clinical implications. <i>International Reviews of Immunology</i> , 2001 , 20, 503-34	4.6	26
93	Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. <i>Developmental Cell</i> , 2020 , 53, 229-239.e7	10.2	25
92	Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. <i>Blood</i> , 2010 , 115, 1669-77	2.2	24
91	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. <i>Immunity</i> , 2019 , 51, 479-490.e6	32.3	22
90	T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 937-43	4.7	21
89	Natural killer cell regulation by microRNAs in health and disease. <i>Journal of Biomedicine and Biotechnology</i> , 2012 , 2012, 632329		20

88	Transcriptional and post-transcriptional regulation of NK cell development and function. <i>Clinical Immunology</i> , 2017 , 177, 60-69	9	19
87	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 347-353	2	19
86	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 740-754	7.8	19
85	Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. <i>Cell Reports</i> , 2020 , 31, 107720	10.6	18
84	Loss-of-Function Mutations Derepress ASH1L to Increase Gene Expression and Promote Leukemogenesis. <i>Cancer Research</i> , 2018 , 78, 3510-3521	10.1	17
83	Hop cleavage and function in granzyme B-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2006 , 281, 37130-41	5.4	16
82	Natural killer cells: biology and application in stem-cell transplantation. <i>Cytotherapy</i> , 2002 , 4, 445-6	4.8	16
81	Human Adaptive Natural Killer Cells: Beyond NKG2C. <i>Trends in Immunology</i> , 2016 , 37, 351-353	14.4	16
80	Memory-like natural killer cells for cancer immunotherapy. <i>Seminars in Hematology</i> , 2020 , 57, 185-193	4	15
79	CD56 regulates human NK cell cytotoxicity through Pyk2. <i>ELife</i> , 2020 , 9,	8.9	12
78	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , 2017 , 6, 2814-2821	4.8	11
77	Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2019 , 134, 1954-1954	2.2	11
76	Human NK cells: SET to kill. <i>Blood</i> , 2011 , 117, 2297-8	2.2	10
75	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1425-30	4.7	9
74	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3693-3693	2.2	9
73	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718	7.8	9
72	Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Blood</i> , 2019 , 134, 3307-3307	2.2	8
71	Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	7

70	Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 1117-1117	2.2	7
69	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15R α Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. <i>Blood</i> , 2015 , 126, 1957-1957	2.2	7
68	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3339-3350	12.9	7
67	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies. <i>Clinical Cancer Research</i> , 2021 , 27, 3744-3756	12.9	7
66	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021 , 9, 1071-1087	12.5	7
65	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 357-362	1.9	6
64	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. <i>Blood</i> , 2007 , 110, 916-916	2.2	6
63	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008 , 112, 2595-2595	2.2	6
62	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. <i>Blood Advances</i> , 2020 , 4, 2387-2391	7.8	5
61	Comment on: Evidence of innate lymphoid cell redundancy in humans. <i>Nature Immunology</i> , 2018 , 19, 788-789	19.1	5
60	Extracellular microRNAs turn on NK cells via TLR1. <i>Blood</i> , 2013 , 121, 4612-3	2.2	5
59	Chronic lymphocytosis of functionally immature natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 120, 924-31	11.5	5
58	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 1623-1623	2.2	5
57	A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012 , 120, 1644-1644	2.2	5
56	Preliminary Results of a Phase 1/2 Clinical Trial of Cnd0-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. <i>Blood</i> , 2014 , 124, 2320-2320	2.2	5
55	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3988-3988	2.2	5
54	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4859-4869	12.9	5
53	Donor Memory-like NK cells Persist and Induce Remissions in Pediatric Patients with Relapsed AML after Transplant. <i>Blood</i> , 2021 ,	2.2	5

52	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , 2009 , 114, 842-842	2.2	4
51	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , 2015 , 126, 1950-1950	2.2	4
50	Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. <i>Cell Reports</i> , 2021 , 35, 109209	10.6	4
49	Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-12	5.2	4
48	Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. <i>Blood</i> , 2013 , 122, 17-17	2.2	3
47	IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells. <i>Blood</i> , 2013 , 122, 2283-2283		3
46	A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2014 , 124, 3099-3099	3.3	3
45	Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 101-101	2.2	3
44	Mystery Solved: IL-15. <i>Journal of Immunology</i> , 2019 , 202, 3125-3126	5.3	2
43	Memory NK Cells Take Out the (Mitochondrial) Garbage. <i>Immunity</i> , 2015 , 43, 218-20	32.3	2
42	Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. <i>Blood</i> , 2019 , 134, 3237-3237	2.2	2
41	The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody. <i>Blood</i> , 2014 , 124, 807-807	2.2	2
40	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015 , 126, 574-574	2.2	2
39	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2021 ,	2.2	2
38	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.. <i>Science Translational Medicine</i> , 2022 , 14, eabm1375	17.5	2
37	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. <i>Haematologica</i> , 2018 , 103, e270-e273	6.6	1
36	CD70 turns on NK cells to attack lymphoma. <i>Blood</i> , 2017 , 130, 238-239	2.2	1
35	"AbroGATAed" human NK cell development. <i>Blood</i> , 2013 , 121, 2579-80	2.2	1

34	A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 8-9	2.2	1
33	Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. <i>Blood</i> , 2019 , 134, 869-869	2.2	1
32	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
31	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 3417-3417	2.2	1
30	MicroRNA-Deficient Murine NK Cells Exhibit Impaired Development and Survival but Enhanced IFN- γ Production In Vitro and In Vivo. <i>Blood</i> , 2011 , 118, 357-357	2.2	1
29	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015 , 126, 689-689	2.2	1
28	End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021 , 138, 3506-3506	2.2	1
27	Comprehensive Evaluation of MicroRNA Genes and Gene Expression Using Next Generation Sequencing in a Patient with Acute Myelogenous Leukemia.. <i>Blood</i> , 2009 , 114, 271-271	2.2	1
26	Human Cytokine-Induced Memory-Like (CIML) NK Cells Exhibit Potent Anti-Leukemia Cytotoxicity and Maintain Memory-Like Functionality After Adoptive Transfer Into Immunodeficient NOD-SCID-Gc-/- (NSG) Mice. <i>Blood</i> , 2013 , 122, 4501-4501	2.2	1
25	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2223-2228	4.7	1
24	Flow cytometry-based murine NK cell cytotoxicity assay. <i>STAR Protocols</i> , 2021 , 2, 100262	1.4	1
23	Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells.. <i>Blood</i> , 2012 , 120, 2159-2159	2.2	0
22	A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 585-596	6.4	0
21	In Vivo Murine Cytokine Models and the Genesis of Cancer 2007 , 199-209		
20	Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1832-1832	2.2	
19	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. <i>Blood</i> , 2021 , 138, 194-194	2.2	
18	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. <i>Blood</i> , 2021 , 138, 3825-3825	2.2	
17	Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors.. <i>Blood</i> , 2006 , 108, 920-920	2.2	

- 16 Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. *Blood*, **2018**, 132, 2929-2929
- 15 Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. *Blood*, **2018**, 132, 1271-1271
- 14 System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. *Blood*, **2019**, 134, 2897-2897 2.2
- 13 Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. *Blood*, **2019**, 134, 2464-2464 2.2
- 12 Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. *Blood*, **2019**, 134, 1550-1550 2.2
- 11 PTEN Regulates Natural Killer Cell Trafficking in Vivo. *Blood*, **2014**, 124, 753-753 2.2
- 10 Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2015**, 126, 3144-3144
- 9 T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. *Blood*, **2015**, 126, 3106-3106 2.2
- 8 Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. *Blood*, **2016**, 128, 5285-5285 2.2
- 7 Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. *Blood*, **2016**, 128, 3419-3419^{2.2}
- 6 Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. *Blood*, **2016**, 128, 550-550 2.2
- 5 The Use of CD34+-Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation. *Blood*, **2016**, 128, 4697-4697 2.2
- 4 Latent Murine Herpesvirus-4 Infection Arms NK Cells.. *Blood*, **2009**, 114, 3678-3678 2.2
- 3 The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B. *Blood*, **2010**, 116, 104-104 2.2
- 2 Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells. *Blood*, **2012**, 120, 3291-3291 2.2
- 1 A Systemic Protein Deviation Score Linked to PD-1 CD8 T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma.. *Med*, **2021**, 2, 180-195.e5 31.7